Leqvio Shortage Update: What Patients Need to Know in 2026

Many patients searching for Leqvio (inclisiran) wonder whether the drug is actually in shortage — because despite it being available since 2021, getting it can still be surprisingly difficult. Here's the most up-to-date information on Leqvio availability in 2026.

Is Leqvio In Shortage in 2026?

No — Leqvio is not on the FDA's official drug shortage list as of 2026. Novartis is actively manufacturing and distributing inclisiran in the U.S., and the drug has been commercially available since its FDA approval in December 2021. In 2024, Leqvio generated $754 million in global revenue, indicating substantial and growing market presence.

However, availability is not the same as accessibility. Patients often face three distinct types of hurdles:

1. Logistical barriers: Not every clinic stocks Leqvio. It must be ordered in advance through specialty distributors.
2. Insurance barriers: Prior authorization is required by virtually all commercial insurers. Denials and appeals can delay treatment by weeks.
3. Clinical model barriers: Because Leqvio must be given in-office, it depends on having a provider relationship and scheduled appointment.

Has Leqvio Ever Been in Shortage?

Leqvio has not appeared on the FDA drug shortage database since its approval. Unlike small-molecule generic drugs, which face manufacturing and supply chain disruptions more frequently, Leqvio is produced by a single large manufacturer (Novartis) with dedicated production infrastructure. This reduces the likelihood of true supply-side shortages.

Why Do Some Patients Feel Like Leqvio Is Unavailable?

When patients report difficulty finding Leqvio, they're usually encountering one of these scenarios:

• Their doctor doesn't stock it. Primary care offices and smaller practices often don't maintain Leqvio inventory because it's a specialty buy-and-bill medication.
• Prior auth is pending or denied. Even when the drug is available at a clinic, insurance may block coverage until authorization is completed.
• They're searching for it at retail pharmacies. Leqvio is never dispensed at retail pharmacies — a common source of confusion.
• They've been referred to a specialist who has a wait list. Cardiology and lipid clinics often have longer appointment wait times.

Leqvio Adoption Rate and Market Trends in 2026

Leqvio's market growth has been steady. As of 2024, it generated $754 million in global sales for Novartis, with the U.S. being a major contributor. The twice-yearly dosing schedule is driving adoption, particularly as the medical community sees advantages in patient adherence — patients who need to come to the clinic only twice a year are more likely to stay on therapy than those self-injecting every 2–4 weeks.

More cardiologists and primary care offices are setting up Leqvio administration programs, meaning access is gradually improving year over year.

What to Do If You Can't Get Leqvio

If you've been prescribed Leqvio but can't access it, here are immediate next steps:

1. Call the Leqvio Service Center (1-833-537-8462) for provider location assistance and insurance support.
2. Ask your prescriber to submit prior authorization if not already submitted.
3. Request a referral to a cardiologist or lipid clinic that regularly administers Leqvio.
4. Use medfinder to locate clinics near you with Leqvio in stock.
5. Discuss bridge therapy with your doctor — alternatives like Repatha (evolocumab) may be an option while you work through Leqvio access.

Summary: Leqvio Availability in 2026

Leqvio is not in shortage. It is manufactured and distributed reliably by Novartis. The challenges patients face are logistical and administrative — not a supply problem. The key is connecting with a provider who stocks it and navigating insurance prior authorization successfully.

If you're struggling to access your Leqvio injection, medfinder can help by calling providers near you to find out who has it available.

Read our guide to alternatives to Leqvio if you're waiting on prior authorization or looking for options.